Trial results for crovalimab, investigating its efficacy and safety versus eculizumab in participants with paroxysmal nocturnal hemoglobinuria (PNH), were posted on ClinicalTrials.gov on 2025-11-10. The Phase 3 study (NCT04434092) aimed to evaluate the non-inferiority of crovalimab in patients not previously treated with complement inhibitors.
Background
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired, life-threatening blood disorder characterized by chronic hemolysis, bone marrow failure, and thrombosis. This study compared crovalimab against eculizumab, another treatment for PNH.
Trial design
The Phase 3 study (NCT04434092) was designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) who had not been previously treated with complement inhibitor therapy. The trial enrolled 210 participants and compared treatment arms of crovalimab and eculizumab.
Key results
The trial evaluated several key outcomes comparing crovalimab to eculizumab:
- For "Percentage of Participants With Transfusion Avoidance (TA)", crovalimab showed 65.7 percentage of participants, compared to 68.1 percentage of participants for eculizumab. The weighted difference in proportion was -2.8 (95.0% CI: -15.67 to 11.14).
- For "Percentage of Participants With Hemolysis Control Measured by LDH", crovalimab achieved 79.3 percentage of participants, while eculizumab achieved 79.0 percentage of participants. The Odds Ratio (OR) was 1.02 (95.0% CI: 0.57 to 1.82).
- For "Percentage of Participants With Breakthrough Hemolysis (BTH)", crovalimab reported 10.4 percentage of participants, versus 14.5 percentage of participants for eculizumab. The weighted difference in proportion was -3.9 (95.0% CI: -14.82 to 5.26).
- For "Percentage of Participants With Stabilization of Hemoglobin", crovalimab showed 63.4 percentage of participants, compared to 60.9 percentage of participants for eculizumab. The weighted difference in proportion was 2.2 (95.0% CI: -11.37 to 16.31).
- For "Change From Baseline in Fatigue Assessed by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale", crovalimab demonstrated a mean change of 7.79 (Standard Error: 0.661), while eculizumab showed a mean change of 5.15 (Standard Error: 0.880). The difference in adjusted mean was 2.64 (95.0% CI: 0.68 to 4.6).
What this means
The results of this Phase 3 study suggest that crovalimab demonstrates comparable efficacy to eculizumab across several key measures for participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitors. The confidence intervals for the differences in transfusion avoidance, hemolysis control, breakthrough hemolysis, and hemoglobin stabilization generally indicate non-inferiority. Notably, the analysis for the change from baseline in fatigue showed a statistically significant difference favoring crovalimab, with its confidence interval not crossing zero.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04434092, titled "A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors," were posted on 2025-11-10 on clinicaltrials.gov.